143 related articles for article (PubMed ID: 34839634)
21. Meta-analysis of metabolic syndrome and prostate cancer.
Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
[TBL] [Abstract][Full Text] [Related]
22. Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome.
Chen Z; Deng J; Yan Y; Li M; Chen C; Chen C; Zhao S; Song T; Liu T; Wen X; Yao Y
Horm Cancer; 2018 Aug; 9(4):278-287. PubMed ID: 29948970
[TBL] [Abstract][Full Text] [Related]
23. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
[TBL] [Abstract][Full Text] [Related]
24. Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
Cicione A; De Nunzio C; Tubaro A; Cantiello F; Manno S; Oliveira C; Lima E; Damiano R
BMC Cancer; 2016 Feb; 16():59. PubMed ID: 26846521
[TBL] [Abstract][Full Text] [Related]
25. The effect of metabolic syndrome on prostate cancer final pathology.
Caliskan S; Kaba S; Özsoy E; Keleş MO; Koca O; Akyüz M; Karaman MI
J Cancer Res Ther; 2019 Mar; 15(Supplement):S47-S50. PubMed ID: 30900620
[TBL] [Abstract][Full Text] [Related]
26. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
27. Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.
Li C; Chen M; Wang J; Wang X; Zhang W; Zhang C
Acta Radiol; 2017 Feb; 58(2):232-239. PubMed ID: 27055916
[TBL] [Abstract][Full Text] [Related]
28. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
30. Can transrectal ultrasound-guided biopsy of the prostate with extended 14-core scheme improve the predictive accuracy of Gleason score and tumor site in prostate cancer treatment?
Dell'Atti L
J BUON; 2015; 20(5):1239-43. PubMed ID: 26537070
[TBL] [Abstract][Full Text] [Related]
31. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.
Waterhouse RL; Van Neste L; Moses KA; Barnswell C; Silberstein JL; Jalkut M; Tutrone R; Sylora J; Anglade R; Murdock M; Shiffman Z; Vandenberg T; Shah N; Carter M; Krispin M; Groskopf J; Van Criekinge W
Urology; 2019 Jun; 128():62-65. PubMed ID: 29660369
[TBL] [Abstract][Full Text] [Related]
33. The relationship between prostate cancer and presence of metabolic syndrome and late-onset hypogonadism.
Kayali M; Balci M; Aslan Y; Bilgin O; Guzel O; Tuncel A; Atan A
Urology; 2014 Dec; 84(6):1448-52. PubMed ID: 25281522
[TBL] [Abstract][Full Text] [Related]
34. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.
Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS
Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550
[TBL] [Abstract][Full Text] [Related]
35. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.
Dell'Atti L; Galosi AB
Asian J Androl; 2018; 20(1):15-18. PubMed ID: 28695864
[TBL] [Abstract][Full Text] [Related]
36. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
[TBL] [Abstract][Full Text] [Related]
37. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic differences between prostate cancers detected during initial and repeat transrectal ultrasound-guided biopsy in Korea.
Park DJ; Kim KH; Kwon TG; Kim CI; Park CH; Park JS; Kim DY; Kim JS; Moon KH; Lee KS
Korean J Urol; 2014 Nov; 55(11):718-24. PubMed ID: 25405013
[TBL] [Abstract][Full Text] [Related]
39. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
40. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.
Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z
Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
